Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors
In this Letter to Blood, Strati and colleagues report that depth of response is associated with durability of benefit in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Patients who achieve a complete remission have longer durations of response than those with partial respon...
Gespeichert in:
| Veröffentlicht in: | Blood 2020-02, Vol.135 (7), p.510-513 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 513 |
|---|---|
| container_issue | 7 |
| container_start_page | 510 |
| container_title | Blood |
| container_volume | 135 |
| creator | Strati, Paolo Schlette, Ellen J. Solis Soto, Luisa M. Duenas, Daniela E. Sivina, Mariela Kim, Ekaterina Keating, Michael J. Wierda, William G. Ferrajoli, Alessandra Kantarjian, Hagop Estrov, Zeev Jain, Nitin Thompson, Philip A. Wistuba, Ignacio I. Burger, Jan A. |
| description | In this Letter to Blood, Strati and colleagues report that depth of response is associated with durability of benefit in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Patients who achieve a complete remission have longer durations of response than those with partial response. The authors provide preliminary evidence associating tumor-associated macrophages with depth of treatment response. |
| doi_str_mv | 10.1182/blood.2019003570 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7019190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120622534</els_id><sourcerecordid>2333604414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-db425bc39b78a77350148edc9e1813ac6b652ce4d88f504bf1575ceec48a8d353</originalsourceid><addsrcrecordid>eNp1kUFvEzEQhS0Eomngzgn5yGWLvbaz3h6QqggKUiQucLa8s7PJoI2d2k4q_j2GlAIHTmPJ7z2Pv8fYKymupLTt22GOcbxqheyFUKYTT9hCmtY2QrTiKVsIIVaN7jt5wS5z_iaE1Ko1z9mFkrY3ve4W7O4GdoQnClsOcX-YsSBPuKecKQZOga83G37whTCUzEtCX3Dk91R2nIZ0LBRouOYw1wl-5pm2gaZ6DIDch5EfEo4EhU7IJw8lpvyCPZv8nPHlw1yyrx_ef1l_bDafbz-tbzYNaN2VZhx0awZQ_dBZ33XK1OUtjtCjtFJ5WA0r0wLq0drJCD1M0nQGEEFbb0dl1JK9O-cejsO-GusHkp_dIdHep-8uenL_3gTauW08ua7irEBrwJuHgBTvjpiLq1gA59kHjMfsWqXUSmhdoS6ZOEshxZwTTo_PSOF-NuV-NeX-NFUtr_9e79Hwu5oquD4LsEI6ESaXobYAlWdCKG6M9P_0H6vRpsk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2333604414</pqid></control><display><type>article</type><title>Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Strati, Paolo ; Schlette, Ellen J. ; Solis Soto, Luisa M. ; Duenas, Daniela E. ; Sivina, Mariela ; Kim, Ekaterina ; Keating, Michael J. ; Wierda, William G. ; Ferrajoli, Alessandra ; Kantarjian, Hagop ; Estrov, Zeev ; Jain, Nitin ; Thompson, Philip A. ; Wistuba, Ignacio I. ; Burger, Jan A.</creator><creatorcontrib>Strati, Paolo ; Schlette, Ellen J. ; Solis Soto, Luisa M. ; Duenas, Daniela E. ; Sivina, Mariela ; Kim, Ekaterina ; Keating, Michael J. ; Wierda, William G. ; Ferrajoli, Alessandra ; Kantarjian, Hagop ; Estrov, Zeev ; Jain, Nitin ; Thompson, Philip A. ; Wistuba, Ignacio I. ; Burger, Jan A.</creatorcontrib><description>In this Letter to Blood, Strati and colleagues report that depth of response is associated with durability of benefit in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Patients who achieve a complete remission have longer durations of response than those with partial response. The authors provide preliminary evidence associating tumor-associated macrophages with depth of treatment response.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2019003570</identifier><identifier>PMID: 31895947</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Female ; Humans ; Letter to ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - immunology ; Macrophages - pathology ; Male ; Middle Aged ; Phenotype ; Pyrazoles - therapeutic use ; Pyrimidines - therapeutic use ; Remission Induction ; Treatment Outcome</subject><ispartof>Blood, 2020-02, Vol.135 (7), p.510-513</ispartof><rights>2020 American Society of Hematology</rights><rights>2020 by The American Society of Hematology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-db425bc39b78a77350148edc9e1813ac6b652ce4d88f504bf1575ceec48a8d353</citedby><cites>FETCH-LOGICAL-c447t-db425bc39b78a77350148edc9e1813ac6b652ce4d88f504bf1575ceec48a8d353</cites><orcidid>0000-0002-6177-7572 ; 0000-0002-1623-3613 ; 0000-0002-1253-630X ; 0000-0002-1908-3307</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31895947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strati, Paolo</creatorcontrib><creatorcontrib>Schlette, Ellen J.</creatorcontrib><creatorcontrib>Solis Soto, Luisa M.</creatorcontrib><creatorcontrib>Duenas, Daniela E.</creatorcontrib><creatorcontrib>Sivina, Mariela</creatorcontrib><creatorcontrib>Kim, Ekaterina</creatorcontrib><creatorcontrib>Keating, Michael J.</creatorcontrib><creatorcontrib>Wierda, William G.</creatorcontrib><creatorcontrib>Ferrajoli, Alessandra</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Estrov, Zeev</creatorcontrib><creatorcontrib>Jain, Nitin</creatorcontrib><creatorcontrib>Thompson, Philip A.</creatorcontrib><creatorcontrib>Wistuba, Ignacio I.</creatorcontrib><creatorcontrib>Burger, Jan A.</creatorcontrib><title>Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors</title><title>Blood</title><addtitle>Blood</addtitle><description>In this Letter to Blood, Strati and colleagues report that depth of response is associated with durability of benefit in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Patients who achieve a complete remission have longer durations of response than those with partial response. The authors provide preliminary evidence associating tumor-associated macrophages with depth of treatment response.</description><subject>Aged</subject><subject>Female</subject><subject>Humans</subject><subject>Letter to</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</subject><subject>Macrophages - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenotype</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Remission Induction</subject><subject>Treatment Outcome</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFvEzEQhS0Eomngzgn5yGWLvbaz3h6QqggKUiQucLa8s7PJoI2d2k4q_j2GlAIHTmPJ7z2Pv8fYKymupLTt22GOcbxqheyFUKYTT9hCmtY2QrTiKVsIIVaN7jt5wS5z_iaE1Ko1z9mFkrY3ve4W7O4GdoQnClsOcX-YsSBPuKecKQZOga83G37whTCUzEtCX3Dk91R2nIZ0LBRouOYw1wl-5pm2gaZ6DIDch5EfEo4EhU7IJw8lpvyCPZv8nPHlw1yyrx_ef1l_bDafbz-tbzYNaN2VZhx0awZQ_dBZ33XK1OUtjtCjtFJ5WA0r0wLq0drJCD1M0nQGEEFbb0dl1JK9O-cejsO-GusHkp_dIdHep-8uenL_3gTauW08ua7irEBrwJuHgBTvjpiLq1gA59kHjMfsWqXUSmhdoS6ZOEshxZwTTo_PSOF-NuV-NeX-NFUtr_9e79Hwu5oquD4LsEI6ESaXobYAlWdCKG6M9P_0H6vRpsk</recordid><startdate>20200213</startdate><enddate>20200213</enddate><creator>Strati, Paolo</creator><creator>Schlette, Ellen J.</creator><creator>Solis Soto, Luisa M.</creator><creator>Duenas, Daniela E.</creator><creator>Sivina, Mariela</creator><creator>Kim, Ekaterina</creator><creator>Keating, Michael J.</creator><creator>Wierda, William G.</creator><creator>Ferrajoli, Alessandra</creator><creator>Kantarjian, Hagop</creator><creator>Estrov, Zeev</creator><creator>Jain, Nitin</creator><creator>Thompson, Philip A.</creator><creator>Wistuba, Ignacio I.</creator><creator>Burger, Jan A.</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6177-7572</orcidid><orcidid>https://orcid.org/0000-0002-1623-3613</orcidid><orcidid>https://orcid.org/0000-0002-1253-630X</orcidid><orcidid>https://orcid.org/0000-0002-1908-3307</orcidid></search><sort><creationdate>20200213</creationdate><title>Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors</title><author>Strati, Paolo ; Schlette, Ellen J. ; Solis Soto, Luisa M. ; Duenas, Daniela E. ; Sivina, Mariela ; Kim, Ekaterina ; Keating, Michael J. ; Wierda, William G. ; Ferrajoli, Alessandra ; Kantarjian, Hagop ; Estrov, Zeev ; Jain, Nitin ; Thompson, Philip A. ; Wistuba, Ignacio I. ; Burger, Jan A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-db425bc39b78a77350148edc9e1813ac6b652ce4d88f504bf1575ceec48a8d353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Female</topic><topic>Humans</topic><topic>Letter to</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</topic><topic>Macrophages - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenotype</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Remission Induction</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strati, Paolo</creatorcontrib><creatorcontrib>Schlette, Ellen J.</creatorcontrib><creatorcontrib>Solis Soto, Luisa M.</creatorcontrib><creatorcontrib>Duenas, Daniela E.</creatorcontrib><creatorcontrib>Sivina, Mariela</creatorcontrib><creatorcontrib>Kim, Ekaterina</creatorcontrib><creatorcontrib>Keating, Michael J.</creatorcontrib><creatorcontrib>Wierda, William G.</creatorcontrib><creatorcontrib>Ferrajoli, Alessandra</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Estrov, Zeev</creatorcontrib><creatorcontrib>Jain, Nitin</creatorcontrib><creatorcontrib>Thompson, Philip A.</creatorcontrib><creatorcontrib>Wistuba, Ignacio I.</creatorcontrib><creatorcontrib>Burger, Jan A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strati, Paolo</au><au>Schlette, Ellen J.</au><au>Solis Soto, Luisa M.</au><au>Duenas, Daniela E.</au><au>Sivina, Mariela</au><au>Kim, Ekaterina</au><au>Keating, Michael J.</au><au>Wierda, William G.</au><au>Ferrajoli, Alessandra</au><au>Kantarjian, Hagop</au><au>Estrov, Zeev</au><au>Jain, Nitin</au><au>Thompson, Philip A.</au><au>Wistuba, Ignacio I.</au><au>Burger, Jan A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2020-02-13</date><risdate>2020</risdate><volume>135</volume><issue>7</issue><spage>510</spage><epage>513</epage><pages>510-513</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>In this Letter to Blood, Strati and colleagues report that depth of response is associated with durability of benefit in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Patients who achieve a complete remission have longer durations of response than those with partial response. The authors provide preliminary evidence associating tumor-associated macrophages with depth of treatment response.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31895947</pmid><doi>10.1182/blood.2019003570</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6177-7572</orcidid><orcidid>https://orcid.org/0000-0002-1623-3613</orcidid><orcidid>https://orcid.org/0000-0002-1253-630X</orcidid><orcidid>https://orcid.org/0000-0002-1908-3307</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2020-02, Vol.135 (7), p.510-513 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7019190 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Female Humans Letter to Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - immunology Macrophages - pathology Male Middle Aged Phenotype Pyrazoles - therapeutic use Pyrimidines - therapeutic use Remission Induction Treatment Outcome |
| title | Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A30%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Achieving%20complete%20remission%20in%20CLL%20patients%20treated%20with%20ibrutinib:%20clinical%20significance%20and%20predictive%20factors&rft.jtitle=Blood&rft.au=Strati,%20Paolo&rft.date=2020-02-13&rft.volume=135&rft.issue=7&rft.spage=510&rft.epage=513&rft.pages=510-513&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2019003570&rft_dat=%3Cproquest_pubme%3E2333604414%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2333604414&rft_id=info:pmid/31895947&rft_els_id=S0006497120622534&rfr_iscdi=true |